Alternatively, proteins with known adjuvant effects that have been used in other vaccines, such as Toll-like receptor agonists [37], plant proteins [38], and viral VLPs like HBsAg or alfalfa mosaic virus coat protein, which have been used in malaria clinical trials [39], could also be explored as alternative carrier proteins. The gene discussed is GOLPH3; the disease is malaria.